If you said no, think again. How Norbauer & Co. and founder Ryan Norbauer found success in an unexpected niche.

GPT-5-Codex now extends this unified setup with deeper engineering capabilities — even running "independently for more than 7 ...

The patient-specific nature of autologous cell therapies presents unique challenges that can best be addressed by a middle path between on-site and centralized manufacturing.

Unlike GPT-5, which is built as a general-purpose AI model, GPT-5-Codex is optimized for what OpenAI calls “agentic coding," ...